ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVO Novo Nordisk

133.32
0.95 (0.72%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,898,760
Bid Price
Ask Price
News -
Day High 133.7484

Low
70.895

52 Week Range

High
138.28

Day Low 131.07
Company Name Stock Ticker Symbol Market Type
Novo Nordisk NVO NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.95 0.72% 133.32 20:00:00
Open Price Low Price High Price Close Price Prev Close
131.57 131.07 133.7484 132.89 132.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
66,580 3,898,760 $ 132.66 $ 517,206,032 - 70.895 - 138.28
Last Trade Time Type Quantity Stock Price Currency
19:59:52 1 $ 132.92 USD

Novo Nordisk (NVO) Options Flow Summary

Overall Flow

Bullish

Net Premium

4M

Calls / Puts

357.14%

Buys / Sells

62.50%

OTM / ITM

92.00%

Sweeps Ratio

0.02%

Novo Nordisk Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
596.04B 4.51B - 232.26B 83.68B 18.56 7.12
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Novo Nordisk News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NVO Message Board. Create One! See More Posts on NVO Message Board See More Message Board Posts

Historical NVO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week133.38135.92130.75133.385,199,221-0.06-0.04%
1 Month124.62138.28118.3003128.756,150,8508.706.98%
3 Months102.74138.28101.71118.835,182,03630.5829.76%
6 Months92.645138.2886.96108.004,836,32640.6843.90%
1 Year71.07138.2870.895102.613,215,88162.2587.59%
3 Years35.375138.2833.29580.681,917,88897.95276.88%
5 Years25.685138.2823.0063.711,717,407107.64419.06%

Novo Nordisk Description

Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Your Recent History

Delayed Upgrade Clock